A Phase 2 Study to Evaluate Efficacy of Calaspargase Pegol-mknl and Decitabine Combined With Venetoclax in Pediatric, Adolescent, and Young Adult Patients With Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia (T-ALL) and T- Cell Lymphoblastic Lymphoma (T-LLy)
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
To learn if giving the study drugs calaspargase pegol-mknl and decitabine in combination with venetoclax can help to control relapsed/refractory T-ALL and T-LLy. The safety of this drug combination will also be studied.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek od 1 miesiąca do 21 lat
- •Diagnoza nawracającej lub opornej białaczki limfoblastycznej T-komórkowej lub chłoniaka limfoblastycznego T-komórkowego
- •Wystarczająco dobry stan ogólny pacjenta
- •Prawidłowa funkcja nerek (klirens kreatyniny ≥30 mL/min)
- •Prawidłowe wyniki testów wątroby (bilirubin całkowity ≤1,5 x norma)
- •Prawidłowe poziomy enzymów trzustki i triglicerydów
- •Dla dziewcząt: ujemny test ciążowy wykonany w ciągu 14 dni przed leczeniem
Simplified criteria — AI translation
Trial details
- Minimum age
- 1 Month
- Maximum age
- 21 Years
- Last updated (source)
- July 23, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
MD Anderson Cancer Center
Houston, United States
Trial contact
David McCall, MD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/24/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.